Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Endo International plc ("Endo" or the "Company") (Nasdaq: ENDP). Investors who purchased or otherwise acquired Endo shares between September 28, 2015 and November 2, 2016 inclusive (the "Class Period"), are encouraged to contact the firm in advance of the January 6, 2017 lead plaintiff motion deadline. If you are a shareholder who suffered a loss during the Class Period, click here to participate. In addition, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights free of charge. You can also reach us through the firm's website at http://www.Goldberglawpc.com, or by email at email@example.com. The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. The complaint alleges that during the Class Period, Endo made false and/or misleading statements and/or failed to disclose that: the Company's subsidiary, Par Pharmaceutical, colluded with several of its industry peers to fix generic drug prices; that this conduct constituted a violation of federal antitrust laws; that Endo's revenues during the Class Period were partially the result of illegal conduct; and that as a result of the above, the Company's public statements were materially false and misleading at all relevant times. On November 3, 2016, Bloomberg News reported that the Justice Department is conducting an antitrust investigation of over a dozen companies, including Par Pharmaceutical, to determine whether they unlawfully colluded with each other to fix generic drug prices. When this news was announced, shares of Endo fell in value, causing investors harm.